Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium longum 35624 + Bifidobacterium longum 1714
- Development stage
- Unknown
- Lead developer
- PrecisionBiotics Group
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium longum 35624 + Bifidobacterium longum 1714 is a dual-strain probiotic combination developed by Novonesis (formerly Precision Biotics) that targets the gut-brain axis. The product combines two specific strains of *Bifidobacterium longum*: strain 35624 (formerly classified as *B. infantis* 35624) and strain 1714. Strain 35624 is recognized for its anti-inflammatory properties and its ability to alleviate gastrointestinal symptoms such as abdominal pain and bloating, particularly in patients with irritable bowel syndrome (IBS). Strain 1714 is a psychobiotic that has been shown to modulate brain activity and reduce cortisol levels, helping to manage stress and anxiety. The combination is marketed for the management of IBS and associated psychological symptoms, and it has been investigated in clinical trials for its effects on fatigue and inflammatory markers in patients with ulcerative colitis.
- Brand names
- IBme DualGut-Brain ResetZenBiome Dual
- Other names
- B. longum 35624 + B. longum 1714Bifidobacterium longum 35624 and Bifidobacterium longum 1714
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on Bifidobacterium longum 35624 + Bifidobacterium longum 1714.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium longum 35624 + Bifidobacterium longum 1714.